Hints and tips:
Related Special Reports
...Merck Mercuriadis, adviser to Hipgnosis Songs Fund, has offered to drop a controversial clause giving him the right to buy the group’s music portfolio as he battles to stay on at the investment trust he...
...As a result of the new valuation, Hipgnosis said its operative net asset value per share would be about $1.2, a sharp fall from the $1.7 reported in September 2023....
...Earnings: Amazon, Merck, Bristol Myers Squibb, UPS, Northrop Grumman, Honeywell, Altria, Hershey, Mastercard and Royal Caribbean report earnings before the opening bell....
...Last week Merck sued the US government over a new law that hands the federal government the power to negotiate prices for some of the most expensive drugs....
...“Pfizer is very good at selling but historically not renowned as having the R&D engine of a Merck or Lilly....
...Merck had been in talks to acquire Seagen last summer, offering about $200 a share, according to people familiar with the matter....
...Analysts have been predicting a boom in biotech M&A since a sharp sell-off in the sector since late last year....
...The contracts will give the UK access to 1.75m additional courses of Merck Sharp and Dohme’s antiviral Lagevrio and an extra 2.5m courses of Pfizer’s Paxlovid pill....
...But some investors remain cautious about this 2027 sales forecast due to a sharp fall in demand for Covid jabs, globally....
...US drugmaker Merck has agreed to buy San Diego-based biotech company Prometheus in a $10.8bn all-cash deal designed to expand its pipeline of novel treatments....
...Lex colleague Elaine Moore meanwhile pointed out in a sharp Top Line column that Google’s search results page is so cluttered with ads that it is not much use any more....
...But there is less activity than some in the market expected, given the sharp falls in valuations. Two healthcare bankers said one reason is that sellers are asking for too much....
...The sharp rebound would calm discussions surrounding whether the US is already in a recession, but not enough to stave off fears of one in 2023....
...He has seen a sharp rise in interest from investors since joining the company 12 years ago. “Back then I would attend maybe a call a month with investors,” he says....
...Merck Covid pill: A group that advises the US Food and Drug Administration is scheduled to meet later today to determine whether to grant emergency use authorisation to Merck’s experimental Covid-19 pill...
...Other chip tool and materials makers such as Applied Materials, Merck and Entegris will also add hundreds of jobs in Taiwan....
...The corporate world now sits at the centre of this debate, in sharp contrast to the way things were in the 20th century....
...In sharp contrast to the speedy and successful development of Covid-19 vaccines, drugs to tackle the virus directly are only just heading into the last stage of trials, with Merck and Pfizer launching the...
...In sharp contrast to the speedy and successful development of Covid vaccines, drugs to tackle the virus directly are only just heading into the last stage of trials, with Merck and Pfizer launching the studies...
...The country confirmed more than 11,500 new cases on Thursday, a sharp increase from the hundreds of daily infections being recorded just weeks ago....
...Good evening, New data today showed US companies added just 210,000 jobs in November, a sharp slowdown from the previous month and the lowest monthly total in nearly a year....
...Soren Christiansen, Merck’s former head of vaccine development, now chief executive of Sharps Technology, said that after early negative data, Merck probably concluded it had “missed the boat” and that mRNA...
...“An end to the sharp rise in prices caused by supply bottlenecks is not in sight in the short term, and the economy should continue to lose momentum in the fourth quarter,” he said....
...Founder Merck Mercuriadis told the Financial Times that Hipgnosis would continue to cherry-pick catalogues over the next two to three years as it doubles its base of songs and delivers on its promise to...
...Merck Sector: PHARMA / HQ: KENILWORTH, us Merck faces a growth challenge because of the loss of exclusivity on its multibillion-dollar cancer drug Keytruda towards the end of the decade....
International Edition